|Bid||3.8500 x 3200|
|Ask||0.0000 x 4000|
|Day's range||4.1650 - 4.3870|
|52-week range||2.4900 - 5.4400|
|Beta (5Y monthly)||1.74|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.00|
What happened Shares of MannKind Corporation (NASDAQ: MNKD), a biotech company that specializes in finding therapies for endocrine and orphan lung diseases, rose 10.4% on Monday. The stock closed at $3.
United Therapeutics' (UTHR) investor focus is likely to have been on sales figures of Tyvaso, Remodulin and Orenitram in the second quarter, as these constitute a vast majority of the total revenues.
Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.